Recent clinical findings are starting to question the long-held difference between cannabinoids and opioids in treating acute pain.
Back in 2018, when I wrote Breaking the Cycle of Opioid Addiction: Supplement Your Opioid Management with Cannabis, I compared the evidence for cannabis and opioids across eight types of pain: central, peripheral, inflammatory, nociceptive, grief-related (mental-emotional), acute, chronic, and pathological pain.
At that time, cannabinoids looked promising for most types of pain, except for acute pain. Opioids had much stronger evidence, especially when quick and significant pain relief was needed.
Now, eight years later, I think it’s time to revisit that distinction.
What Has Changed?
Research in this area has grown considerably. The CannaKeys Acute Pain Research Dashboard now lists 297 studies, including 98 primary studies, 24 double-blind clinical trials, and three clinical meta-analyses. The broader collection also includes related and preclinical research.
The results are mixed, which makes sense given the different types of acute pain, cannabinoid formulas, doses, and treatment settings. Some studies show little benefit, but others suggest real improvements in pain management or lower opioid use.
For example, a 2025 systematic review on acute postoperative pain found conflicting results and not enough consistency between trials to draw solid conclusions.
Still, there’s an interesting idea emerging: cannabinoids might not have to replace opioids to make a difference. They could help lower the amount of opioid medication needed for good pain control.
A New Clinical Trial Worth Watching
A randomized, placebo-controlled trial published in October 2026 in the Journal of Cannabis Research adds another interesting detail.
Researchers enrolled 69 patients who came to the emergency department with acute radicular pain, which is often felt as severe shooting or radiating pain from irritation or compression of a spinal nerve root. A classic example is sciatica.
Patients received either a placebo or a single sublingual dose of a formula with THC, CBD, and terpenes, along with access to intravenous morphine.
The results stood out.
Over 24 hours, patients who got the higher cannabinoid dose (19.8 mg THC and 19.8 mg CBD, plus terpenes) needed an average of 17.4 mg of morphine, while the placebo group needed 33.2 mg.
That’s about half the total amount of morphine used by the placebo group.
Just as interesting, researchers found no significant difference in reported pain intensity between the two groups.
The study was small, and three patients who received cannabinoids experienced brief hallucinations. Still, the results add to the evidence suggesting that some cannabinoid formulations may help reduce opioid requirements without compromising short-term pain control.
What Does This Mean for Clinicians?
There are a few practical points to keep in mind.
First, the specific formulation is important. Results from a THC/CBD/terpene mix don’t automatically apply to CBD alone, THC alone, or other cannabis products.
Second, the kind of acute pain matters. Radicular pain involves both neuropathic and inflammatory mechanisms. So, these findings might not apply the same way to postoperative, traumatic, or other types of acute pain.
Third, reducing opioid use isn’t the same as replacing opioids. The trial showed less morphine was needed over 24 hours, but it didn’t establish that cannabinoids alone provide equivalent pain relief or prevent opioid addiction.
Finally, choosing the right patients and keeping safety in mind is crucial. THC-containing products can cause psychoactive effects, sedation, and impairment, especially when used with other medications that affect the brain. Clinicians also need to consider individual risks, monitoring needs, and relevant regulations.
Revisiting an Earlier Conclusion
Looking back at my 2018 review, I’m more and more convinced that we should rethink where acute pain fits in the evidence. It’s not because cannabinoids have been proven to work better than opioids for acute pain. They haven’t.
But new evidence suggests that using cannabinoids alongside standard pain treatments might play a bigger role than we thought before.
For clinicians, the question may be changing from Can cannabinoids replace opioids? to Can we manage pain effectively while reducing unnecessary opioid use? That’s a question worth exploring, especially given the risks associated with prolonged opioid use.
Eight years ago, acute pain was the one category where I felt opioids had the clear advantage. Today, I’m less certain that distinction still holds.
And that’s precisely why we need to keep following the evidence.
Raz, N., Eyal, A.M., Mua, H. et al. Opioid-sparing effect of a cannabinoid formulation in treating acute radicular pain: a randomized controlled trial. J Cannabis Res (2026).
